Research & Development
Policy & Regulation
Trends & Finance
Blood volume diagnostic firm Daxor closes $2.1M offering of common stock
The New York firm plans to use the net proceeds to develop its products, fund capital expenditures, or invest in or acquire other businesses, among other potential uses.
November 17, 2022
Genetron Health receives minimum-bid share price notification from Nasdaq
The company said it has 180 days, or until April 26, 2023, to regain compliance under the Nasdaq listing rules.
November 7, 2022
Quotient to effect reverse stock split, regain Nasdaq compliance
Its ordinary shares are expected to begin trading on the Nasdaq composite on a split-adjusted basis on November 3.
October 31, 2022
Epigenetics testing firm Cardio Diagnostics goes public on Nasdaq
At the core of its cardiovascular solutions is the Integrated Genetic-Epigenetic Engine, developed at the University of Iowa.
October 26, 2022
OpGen closes $3.38M offering to support U.S. commercialization of molecular panel
The firm announced it has closed a $3.38 million registered direct offering with a single institutional investor.
October 4, 2022
Biosensor developer Know Labs goes public on the NYSE
After the close of trading Thursday, the company announced the pricing of an underwritten public offering of 3.6 million shares at $2.00 per share; it granted to the underwriter a 45-day option to purchase up to 540,000 additional shares at the same price.
September 15, 2022
DNA forensic evidence frees Ohio man of rape, attempted rape
‘Good’ cholesterol worse for some adults: NIH study
Empatica receives FDA clearance for digital biomarker platform, closes Series B financing
AnchorDx enrolling U.S. clinical trial for bladder cancer assay
Week in Review: Elizabeth Holmes sentenced; good cholesterol worse for some adults; earlier type 2 diabetes diagnosis; and more
Chembio Diagnostics applies for FDA CLIA waiver for HIV, syphilis test
BioAffinity Technologies goes public with $7.9M IPO
Gross proceeds from the offering are estimated to be about $7.9 million before deducting underwriting discounts and commissions and other estimated offering expenses.
August 31, 2022
Accelerate Diagnostics prices $35M stock offering
Its gross proceeds from the offering, before deductions, are expected to be $35 million, said Accelerate, a Tucson, AZ-based developer and supplier of identification and antimicrobial susceptibility tests (ID/AST) for bloodstream infections including sepsis.
August 18, 2022
LumiraDx Q2 revenues down 49% on drop in COVID testing
For the second quarter ended June 30, the London-based firm posted revenues of $44.7 million, compared to revenues of $87.2 million in Q2 2021, short of Wall Street analysts' average estimate of $53.1 million.
August 17, 2022
Agilent Technologies Q3 revenues rise 8%
For the fiscal third quarter ended July 31, Agilent's Life Sciences and Applied Markets Group posted revenues of $1.02 billion, a year-over-year increase of 14%; the CrossLab Group posted revenues of $359 million, a year-over-year increase of 5%; and the Diagnostics and Genomics Group posted revenues of $340 million, a year-over-year decrease of 2%.
August 16, 2022
Sophia Genetics revenues up 15% on platform volumes
The firm said that its year-over-year revenue growth on a constant currency basis, excluding COVID-19-related revenues, was 36%.
August 8, 2022
VolitionRx prices $6M public offering
The company said that gross proceeds to Volition from the offering are expected to be $6 million. Volition also granted the underwriter a 30-day option to purchase up to an additional 450,000 shares of its common stock at the public offering price. The offering is expected to close on or about August 2.
July 28, 2022
Page 1 of 3